Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

SynVent IDD platform

SynVent: Experienced at every step – Concept to Clinic

SynVent’s current portfolio across  integrated drug discovery projects, therapeutic areas.

We collaborate with a diverse range of organizations, each of which faces distinct challenges:

  • Virtual biotech companies that bring innovative approaches to a target or pathway and need support to transform their concepts into tangible outcomes
  • Small biotech companies equipped with groundbreaking platform technologies but need support for the remaining stages of their drug discovery process
  • Mid-sized and large pharmaceutical companies looking to outsource a drug discovery program while minimizing overhead costs to deliver a candidate
  • University spin-outs seeking a collaborator to validate and develop their ideas to facilitate their next round of funding
  • Non-profit organizations in search of a partner with extensive expertise across target classes and therapeutic domains to address unmet diseases
  • Venture capital funders who need a dependable, expert team to effectively guide a program toward a go/no-go decision.

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details